Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.54 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7050439 | 0.86 | ALDH1A1 (0.51) | ALOX5PTGDR2ALDH1A1MAPTLMNA | |
| SCHEMBL1398615 | 0.84 | ALDH1A1 (0.62) | ALOX5PTGDR2ALDH1A1MAPTLMNA | |
| SCHEMBL5816209 | 0.82 | CDC7 (0.59) | ALOX5PTGDR2ALDH1A1MAPTPTGS2 | |
| SCHEMBL14705597 | 0.81 | KDM4E (0.53) | PTGDR2ALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL14705598 | 0.81 | ALOX5 (0.47) | ALOX5PTGDR2ALDH1A1MAPTPTGS2 | |
| SCHEMBL7050104 | 0.76 | NPC1 (0.51) | ALOX5PTGDR2ALDH1A1MAPTLMNA | |
| SCHEMBL1919237 | 0.76 | TRPM8 (0.54) | ALOX5ALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL7051373 | 0.75 | PTGDR2 (0.49) | PTGDR2ALDH1A1LMNAKDM4EGAA | |
| SCHEMBL2692137 | 0.75 | F2RL3 (0.44) | ALDH1A1MAPTLMNAKDM4EGAA | |
| SCHEMBL7053834 | 0.74 | ALDH1A1 (0.58) | ALOX5PTGDR2ALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6602895-B2 | Inhibitors of factor Xa with a neutral P1 specificity group | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-05 | — | — | US | disclosed |
| US-20030092740-A1 | Inhibitors of factor Xa with a neutral P1 specificity group | GALEMMO ROBERT A (US) | 2003-05-15 | — | — | US | disclosed |
| US-6403620-B1 | ANTICOAGULANT AGENTS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-11 | — | — | US | disclosed |
| EP-0991625-A2 | INHIBITORS OF FACTOR XA WITH A NEUTRAL P1 SPECIFICITY GROUP | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 2000-04-12 | — | — | EP | disclosed |
| US-5998424-A | ANTICOAGULANTS | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1998057937-A2 | INHIBITORS OF FACTOR XA WITH A NEUTRAL P1 SPECIFICITY GROUP | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092740-A1 | Inhibitors of factor Xa with a neutral P1 specificity group | F12, F11, SERPINC1 | ALOX5 2751/4885PTGDR2 2199/4885ALDH1A1 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.